Anke Reinacher-Schick

10PUBLICATIONS
87CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 07, 2025
Heterogeneity of treatment preferences in the absence of guideline recommendations - a case vignette study in colorectal cancer tumor boards in Germany, Austria and Switzerland.

Johannes Soff, Stefan Rolf Benz, Christoph Kowalski

|Aug 13, 2025
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Rainer Fietkau, Michael Ghadimi, Robert Grützmann

|Jul 30, 2025
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.

Alexej Ballhausen, Susanna Swoboda, David Horst

|Nov 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy.

Joseph Tintelnot, Lisa Paschold, Eray Goekkurt

|Jun 24, 2024
Impact of preoperative chemotherapy on surgical results in 139 patients with locally advanced pancreatic cancer.

Marvin Petrikowski, Tim Fahlbusch, Anke Reinacher-Schick

|Jun 23, 2023
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.

Sebastian Stintzing, Kathrin Heinrich, David Tougeron

Pageof 2

Frequent Collaborators

5 joint publications

Sebastian Stintzing

4 joint publications

Dominik Paul Modest

4 joint publications

Volker Heinemann

3 joint publications

Annabel Helga Sophie Alig